Dr Reddy's Laboratories has completed the acquisition of GlaxoSmithKline's (GSK) oral penicillin facility and product portfolio in the US. Dr. Reddy's assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, US, and rights for the Augmentin and Amoxil brands in the United States.
GSK would retain the existing rights for these brands outside the US. The agreement to acquire the facility was signed by Dr Reddy's and GSK in November 2010. As per the company the buy was in line with its strategy to scale up its generics business in North America. It would also bring in an opportunity to explore additional synergy with its other businesses.
In 2009, Dr Reddy's had entered into a strategic partnership with GSK through which GSK gained access to a basket of 100 products of Dr Reddy's branded pharmaceutical segment to be sold in emerging markets.crackcrack
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |